Murase T, Mitsuya H, Honda N, Fukatu H, Aota Y, Shinoda M, Yoshida K, Sobajima T, Ohishi M, Tsumura Y
Department of Urology, Nagoya University School of Medicine.
Hinyokika Kiyo. 1989 Jan;35(1):179-85.
Clinical effect of Estracyt was investigated in prostatic cancer patients. Twenty seven patients had been previously treated and 20 had not received prior treatment. Improvement rate of subjective symptoms was 85% in the previously untreated patients and that of objective findings was 85%, while those rates were 44% and 50% in the previously treated patients, respectively. Most of the adverse reactions were changes in mamma and mammary papilla which were considered to be due to the estrogenic activity.
对前列腺癌患者进行了雌莫司汀的临床疗效研究。27例患者曾接受过治疗，20例未曾接受过前期治疗。在未接受过治疗的患者中，主观症状改善率为85%，客观检查结果改善率为85%；而在曾接受过治疗的患者中，这两个比率分别为44%和50%。大多数不良反应是乳房和乳头的变化，这些被认为是由雌激素活性引起的。
